Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | CDX-1140 + CDX-301 + Poly ICLC |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
CDX-1140 | CDX 1140|CDX1140 | CD40 Antibody 14 | CDX-1140 is an antibody that binds CD40 and activates signaling, potentially resulting in enhanced anti-tumor immune response (Blood, 128(22), 1848, PMID: 30382327). | |
CDX-301 | Mobista|CDX 301|CDX301 | Mobista (CDX-301) is a recombinant Flt3 ligand that binds to and activates the Flt3 receptor, potentially leading to proliferation of immune precursor cells (PMID: 25915810). | ||
Poly ICLC | Hiltonol | Hiltonol (poly ICLC) is a synthetic double stranded RNA complex, which induces interferon production and stimulates anti-tumor immune response (PMID: 22126373). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04616248 | Phase I | CDX-1140 + CDX-301 + Poly ICLC | In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors | Recruiting | USA | 0 |